• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against cancer The present invention relates to the formation of nanoconjugates that exhibit antitumor activity, mainly against advanced prostate cancer, but without ruling out others. The nanoconjugates are formed by dendritic systems (dendrimers or dendrons) and neuropeptides. The dendritic molecules are mainly of carbosilane structure with ammonium functions in the periphery. The peptides are preferably of the glucagon/secretin family (eg: VIP, GHRH, PACAP). The combination of these two systems gives rise to a nanoconjugate with anticancer properties, different from those of its precursors separately. The antitumor activity is reflected in the inhibition of growth and death of advanced prostate cancer (PC3) tumor cells and, in addition, these nanoconjugates favor cell adhesion and prevent processes of tumor cell migration, ie metastasis processes. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2677242A1
    申请号:ES201700069
    申请日:2017-01-31
    公开日:2018-07-31
    发明作者:Francisco Javier De La Mata De La Mata；Maria José CARMENA SIERRA；Rafael Gómez Ramírez；Javier Sánchez-Nieves Fernández；Laura MUÑOZ MORENO；María SANCHEZ MILLA
    申请人:Universidad de Alcala de Henares UAH；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    30
    NANOCONJUGADOS FORMED FOR DENDRITIC MOLECULES AND PEPTIDES AS ANTITUMURAL AGENTS AGAINST CANCER.
    The present invention relates to the formation of nanoconjugates that exhibit antitumor activity, mainly against advanced prostate cancer. The nanoconjugates are composed of dendritic systems (dendrons and dendrons) and neuropeptides. The dendrophic molecules are mainly of carbosilane structure and with ammonium functions in the periphery and the peptides are preferably of the glucagon / secretin family (eg, VIP, GHRH, PACAP).
    STATE OF THE PREVIOUS TECHNIQUE
    Prostate cancer (CP) is the second most frequent among men worldwide (Siegel, et al., Cancer J. Clin., 2014, 64, 9). It is a heterogeneous tumor with a slow but constant growth rate, which evolves from a localized stage and with sensitivity to androgens to an advanced stage in which said sensitivity is lost. Treatment depends on the stage of the disease; if discovered early it can be treated satisfactorily by different procedures; Unfortunately, when tumor cells invade the area of the gland, it evolves into a metastasis phenotype and current treatments offer no cure. In addition, this type of cancer has a tendency to metastasize to bone (90%) and lung (46%) (Bubendorf, et al., Hum Pathol, 2000, 31, 578), which are metastases with a lower prognosis for healing. .
    Neuropeptides such as vasoactive intestinal peptide (VIP), growth hormone releasing hormone (GHRH), or the pituitary adenylate cyclase activating peptide (PACAP), belonging to the glucagon / secretin family (Cardoso, et al., BMC Evol. Biol., 2010, 10, 13), have a wide biological activity in the organism and are very involved in the etiopathogenesis of PC. VIP has a protumoral effect on prostate tumors, increasing proliferation, protecting it from apoptosis (Gutierrez-Cahas, et al., Br. J. Pharmacol., 2003, 139, 1050), increasing angiogenesis (Collado, et al. ., Peptides (Amsterdam, Neth.), 2007, 28, 1896), metastasis (Fernandez-Martinez, et al., Prostate, 2009, 69, 774) and helping the progression of cancer towards more aggressive stages (Fernandez- Martinez, et al., Cancer Lett., 2010,
    5
    10
    fifteen
    twenty
    25
    30
    299.11). Its mechanism of action is through GPCR type receivers: PACi, VPACi, VPAC2 and FPRL-1 (Garcia-Femandez, eta!., Peptides, 2003, 24, 893, El Zein, etal., 2008, 83, 972) . For its part, GHRH also acts through GPCR receptors, in this case hGHRH and its different variants of splicing (SVs). Its function is to regulate the secretion of growth hormone (GH) (Martinez-Moreno, et ai, Gen. Comp. Endocrinol., 2014, 199, 38), which in turn induces the activation of the IGF-1 factor (Gan , et ai, Mol. Endocrinol., 2013, 27, 1969), which plays a crucial role in malignancy, metastasis and tumorogenesis in several tumors such as CP (Bellyei, et ai, Cancer Lett., 2010, 293, 31 , Shevah, et ai, Growth Horm. IGF Res., 2007, 17, 54, Takeuchi, et ai, Mol. Cell. Endocrinol., 2014, 384, 117).
    Both VIP and GHRH have an autocrine and paracrine action in prostate cancer cells (Gutierrez-Canas, et ai, Br. J. Pharmacol., 2003, 139, 1050, Busto, et ai, Proc. Natl. Acad. Sci. USA, 2002, 99, 11866), so there is always a basal concentration of both inside the cell and its surroundings, which "feed" the cells. Both join their membrane GPCRs receptors and initiate a cascade of events mediated by the increase of cAMP as the second main messenger, although it can also be mediated by others such as Ca2 +. Very promising antagonists have been designed for both peptides in the treatment of various human tumors (Plonowski, etai, Int. J. Cancer, 2002, 98, 624, Fahrenholtz, et ai, Proc. Natl. Acad. Sci. USA, 2014, 111, 1084, Munoz-Moreno, et ai, Invest. New Drugs, 2014, 32, 871). However, antagonists continue to have problems, since although their half-life is longer than that of the original peptides, it is still short.
    Dendritic systems (or molecules) (dendrimers and dendrons) are hyperbranched macromolecules of a perfectly defined and polyfunctionalized structure. The dendrlmeros are of spherical morphology with a multivalent surface and the dendrons are of curia type topology, also with a multivalent surface and an additional active position in the apex of this curia called focal point. Dendrons can be considered as dendrimer fragments, and in fact, one of the synthetic dendrimer procedures uses precisely dendrons as a building block (Sanchez-Nieves, et ai, Tetrahedron, 2010, 9203). In addition, in the case of dendrlimers and dendrons with the same type of skeleton, the same type of
    5
    10
    fifteen
    twenty
    25
    30
    reactions for the synthesis of both topologies (Fuentes-Paniagua, et al., RSC Adv., 2016, 6, 7022). Both dendrimeros and dendrones allow to arrange a large number of functional groups producing a unique and different effect to that found in these same groups if they were individually (Astruc, et al., Chem. Rev., 2010, 110, 1857, Newkome, et al., Dendrimers and Dendrons, Wiley-VCH Verlag GmbH, 2004, 1).
    Dendritic systems have been used as transporters of drugs or antitumor nucleic acids because of their ability to absorb “in vivo” in tumor areas and internalize treatment in cancer cells due to the EPR (Enhanced Permeability and Retention) effect (Chen, et al., World J. Surg. Oncol., 2012, 10, 3, Jain, eta!., Eur. J. Pharm. Biopharm., 2014, 87, 500, Huang, etal., Biomacromolecules, 2014, 15, 915). This effect is based on the fact that the tumor areas with greater angiogenic activity have a greater amount of blood vessels whose endothelium has a greater permeability (the cells are usually separated between 200-600 nm) than in a “healthy” blood vessel, allowing the passage of substances through it more easily.In addition, once the dendrimer leaves the blood vessel it accumulates in the tumor area, since the flow of the lymphatic system is reduced in these areas and it is more difficult to return to the circulatory system, on the contrary what or It runs with the small molecules that return to the bloodstream (Azzopardi, et al., J. Antimicrob. Chemother., 2013, 68, 257, Fang, et al., Adv. Drug Delivery Rev., 2011, 63, 136, Konno, et al., Cancer, 1984, 54, 2367).
    To act as nucleic acid transporters, cationic systems are generally employed, such as cationic dendritic molecules, which by electrostatics interaction with them, allow such acids to be protected from degradation by nucleases (Svenson, et al., Advanced Drug Delivery Reviews, 2012 , 64, 102). Similar strategies have been used for studies of peptide therapies, such as against human immunodeficiency virus (HIV) (Ionov, et al., Biochimica et Biophysica Acta, 2015, 1848, 907). Also in these nanoconjugates the electrostatics interaction between the dendritic system and peptide is used to stabilize the peptides and transport them to the cells, where their release facilitates their activity.
    5
    10
    fifteen
    twenty
    25
    30
    DESCRIPTION OF THE INVENTION
    The present invention provides the preparation of active nanoconjugates against advanced prostate cancer. These systems are made up of dendritic molecules (dendrimers and dendrons) and neuropeptides. Preferably, the dendritic macromolecules are of carbosilane structure, mainly with cationic functions in the periphery, and the neuropeptides are of the glucagon / secretin family, mainly VIP, GHRH and PACAP. These nanoconjugates are formed by a combination of the dendritic molecule and the corresponding peptide in the necessary proportion. The formation of the nanoconjugate allows to create a system that presents anticancer properties in advanced prostate cancer and avoid metastasis.
    Therefore, a first aspect of this invention relates to a combination of peptide and dendritic molecule comprising:
    - A neuropeptide, preferably from the glucagon / secretin family.
    This peptide is preferably vasoactive intestinal peptide (VIP), growth hormone releasing hormone (GHRH) or pituitary adenylate cyclase activating peptide (PACAP), without ruling out others that have a similar activity.
    - A dendritic compound, which refers in the present invention to a highly branched macromolecule where the growth units, branches or branches have carbosilane skeleton.
    This dendritic compound is preferably a dendrimer, with a spherical shape that has a growth nucleus of the polyfunctional molecule. The units, branches or branches of growth have carbosilane skeleton and the outer layer, surface or periphery of! dendrimero incorporates preferably cationic groups. The skeleton and structure of these carbosilane dendrimer with different nuclei have been previously described (see for example ES-2444490).
    The dendritic compound can also be of the dendritic or dendron cradle type, which refers to a very branched cone-shaped macromolecule and which is defined by a focal point, the units, branches or branches of growth, which start from said focal point and the outer layer, surface or periphery of said branches that incorporates functional groups. The skeleton and structure of these dendrons
    5
    10
    fifteen
    twenty
    25
    30
    carbosilanes with different focal points have been previously described (see for example ES-2444490).
    In another preferred embodiment, the dendritic compound further comprises, at the outer layer of the dendrimer or dendron or at the focal point of the dendron, at least one functional group of different nature to the rest of the functional groups, and which can be selected from a molecule etiquette, a steering group or an active substance. These dendrimers and dendrons have been previously described (see for example ES-2444490; P201500669).
    The term "label molecule" refers in this description to any biorecognizable substance, chromophore, fluorophore or any other group detectable by spectrophotometric, fluorometric, optical microscopy, fluorescence or confocal, antibody and / or NMR techniques, and which easily allows the detection of another molecule that alone is difficult to detect and / or quantify. For example, and without limitation, fluoroforo is selected from a list comprising cytochrome, fluorescein, rhodamine and dansyl.
    By "director group" is meant a molecule or functional group capable of directing the dendritic compound specifically to a type of cell or to a specific area of a cell, such as folic acid, a serial peptide or an antibody, among other known by any person skilled in the art, said lead group can be previously functionalized to bind the dendritic compound.
    By "active ingredient" or "drug" is meant in the present invention any purified chemical substance used in the prevention, diagnosis, treatment, mitigation or cure of a disease; to prevent the occurrence of an unwanted physiological process; or to modify physiological conditions for specific purposes Said active ingredient is capable of binding directly to the dendritic compound or with a previous modification of its structure for it.
    The present invention also relates to the uses in biomedicine of the peptide / dendritic molecule combinations.
    5
    10
    fifteen
    twenty
    25
    30
    Preferably, this investment is for the development of drugs for the treatment of prostate cancer. However, other types of cancers are not excluded. More preferably, the present invention focuses on the treatment of advanced prostate cancer.
    Another aspect of the present invention relates to the use of the nanoconjugates of the invention for the preparation of a medicament. More preferably, the medicament is used for the prevention and / or treatment of prostate cancer.
    Another aspect of the present invention relates to a pharmaceutical composition comprising at least one dendritic molecule and a neuropeptide, as described above, and a pharmaceutically acceptable carrier. In addition, this pharmaceutical composition may comprise another active ingredient, preferably with antitumor properties. The antitumor may be doxorubicin, methotrexate or platinum compounds or others with antitumor properties.
    The "pharmaceutically acceptable vehicles" that can be used in said compositions are the vehicles known to one skilled in the art. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels , solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration.
    In the sense used in this description, the term "therapeutically effective amount" refers to the amount of the composition calculated to produce e! desired effect and, in general, will be determined, among other causes, by the characteristics of the composition, the age, condition and history of the patient, the severity of the disease, and the route and frequency of administration.
    Throughout the description and the claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and characteristics of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figures are provided by way of illustration, and are not intended to be limiting of the present invention.
    5
    10
    fifteen
    twenty
    25
    30
    Figure 1. Example of second generation cationic carbosilane dendrimer with polyphenolic type nucleus ([G203 (S-NMe2R) i2] 12+; (R = (CH2) 20H (1), Me (2)).
    Figure 2. Exemplary third-generation cationic dendron carbosilane. For example, X = OH, NH2, SH, or others of interest.
    Figure 3. Cell viability in the presence of VIP and GHRH peptides, dendrimer 1 and nanoconjugate peptide / dendrimer of PC3 cells. * p <0.05; ** p <0.01; *** p <0.001.
    Figure 4. Results of adhesion assays on PC3 cell lines of dendrimer 1 alone or attached to the VIP or GHRH peptide. Mean values ± E.S.M., of 6 experiments, ** p <0.01 and *** p <0.001 versus control values are shown; # p <0.05 and ## p <0.01 with respect to the dendrimer.
    Figure 5. Migration of PC3 cells at time 0, 6 and 24 hours with the different treatments.
    Figure 6. Migration of PC3 cells at 6 h. of treatment. Mean values ± E.S.M., of 1 experiment, with 6 duplicates are shown. * P <0.05 versus control values.
    Figure 7. Flow cytometry test in PC3 cells 24 hours after treatment. Mean values ± E.S.M., of 2 experiments, * p <0.05 versus control values are shown.
    EXAMPLES
    Dendrimers and dendrons.
    Two types of second generation carbosilane structure dendrimer functionalized with different ammonium groups (G203 (S-NMe2R +) i2; R = (CH2) 2OH (1), Me (2), Figure 1) were analyzed.
    5
    10
    fifteen
    twenty
    25
    30
    Formation of nanoconjugates.
    The formation of the nanoconjugates was carried out by mixing in dissociation, preferably aqueous in the presence or absence of buffer, the dendritic molecules and the corresponding peptides, in the proportion of interest.
    In a preferred embodiment, the mixtures were made directly on the tumor cells. In a well containing 25 x 104 cells / ml, 445 pL of RPMI-1640 medium with 10% fetal bovine serum (FBS) with 1% antibiotic and antifungal (peniciiin / streptomycin / amphotericin) were added. Next, 50 pL of a 10-8 M dissociation of the dendritic system performed in the same medium mentioned above was added. Then 5 pL of peptide (VIP stock 10'4 M or GHRH stock 10'5M) were added.
    In another preferred embodiment, the nanoconjugates may also be formed prior to their addition on the well containing the cells. For this, a dissociation is prepared containing 45 pL of RPMI-1640 medium with 10% fetal bovine serum (FBS) with 1% antibiotic and antifungal (peniciiin / streptomycin / amphotericin). Then 50 pL of a 10-8 M dissociation of the dendritic system performed in the same medium mentioned above are added. Then 5 pL of peptide (VIP stock 10-4 M or GHRH stock 10'5M) are added.
    ANTITUMORAL ACTIVITY OF NANOCONJUGADOS PEPTIDO / DENDRIMERO IN FRONT OF CANCER DE PROSTATA
    MATERIALS AND METHODS
    Reagents
    As controls for cell toxicity tests, the same medium used in the dissociation of nanoconjugates was used.
    Cells
    The human prostate cell line, PC3, representative of an androgen-independent stage of prostate cancer, obtained from ATCC (American Type Culture Collection) is used. The cells are kept in RPMI-1640 medium with 10% serum
    5
    10
    fifteen
    twenty
    25
    30
    Fetal bovine (FBS) with 1% antibiotic and antifungal (penicillin / streptomycin / amphotericin). The cells are stored at 37 ° C in a humid environment and with 5% of
    C02.
    Toxicity test by reduction of tetrazolium sates.
    This technique is a colorimetric assay based on the selective ability of living cells to reduce 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide in formazan insoluble crystals. This method allows to determine the lethal effect of the compounds under study on cell metabolism, since cell damage results in a decrease in the mitochondrial activity of the cell, being able to measure the cytotoxicity of these molecules. This test was carried out according to the manufacturer's instructions (MTT, Sigma-Aldrich, St Louis, USA). PC-3 cells (15 x 104 cells / ml) are seeded in 24-well plates. After 24 hours the culture medium is removed and treated. The supernatant containing the treatment is removed at 24 hours and replaced by 500 pi of a culture medium to which 25 pi of MTT in PBS of a concentration of 1 mg / ml is added. After 1.5 hours of incubation under culture conditions, the removal of the supernatant with the excess of unreacted MTT is preceded. Formazan crystals are subsequently dissolved with 100 pi of isopropanol. The absorbance is read at 570 nm by subtracting the background measured at 620 nm. The relative cell viability (%) with respect to the control (untreated cells) is calculated based on the formula: [A] test / [A] control x 100.
    Adhesion tests.
    The suspension of PC3 cells (25 x 104 cells / ml) is separated into several fractions that depend on the number of treatments to be performed and are kept in suspension for 1 hour, at 37 ° C, with agitation every 10 minutes. The plates with the collagen that acts as matrix, are prepared with 100 pi of type I collagen (8 pg / cm2) diluted in 10 mM acetic acid / well, in P-96 plates, for 1 hour, at 37 ° C, in dry atmosphere to achieve a complete fixation to the well. After that time, the collagen is aspirated and the plate is washed four times with PBS. 100 pi of the previously treated cell suspension is added to each well and the medium is aspirated at 40 minutes. Finally, the evaluation of the cells attached to the collagen is continued by means of an MTT test, where 100 pi of serum-free medium and 0.1 mg / ml MTT are added to each well. After removal of the supernatant with excess MTT that does not react,
    5
    10
    fifteen
    twenty
    25
    30
    Dissolve the formazan crystals with 100 pi of isopropanol. The absorbance at 570 nm is measured by subtracting the background at 620 nm. The results are expressed in% with respect to the absorbance of the control (untreated cells): [A] test / [A] control x 100.
    Migration essay.
    PC3 cells (20 x 104 cells / ml) are seeded in 24-well plates. The cells are treated with the dendrimer and the peptides 24 hours. After removing the medium, a wound is made in each well and the progression of its closure at different times is followed by photographs taken with the inverted microscope coupled to the Motic camera. The results are processed by measuring the size of the wound and the% of the progress of the wound is plotted against that of zero time.
    Cell Cycle Assays
    PC3 cells (7.5 x 104 cells / ml) are seeded on P-6 plates and held for 24 h to achieve adhesion, at which time they are deprived with serum-free medium for 24 h. After this time, the different treatments are performed and at 24 hours, the cells are washed with PBS, raised with trypsin and centrifuged. The precipitate of cells is fixed and permeabilized with 70% cold ethanol, for 5 days, at 4 ° C. Then, the cells are centrifuged to remove the ethanol and washed with PBS. Finally, they are resuspended in a staining solution (PBS, 50 mg / ml of propidium iodide (IP) and 10 pg / ml of RNase), before analysis by flow cytometry with FACSCalibur. The amount of DNA that is distributed in the different phases of the cell cycle is analyzed with the Cyflogic v 1.2.1 program.
    Statistic analysis.
    Data are expressed as the mean ± S.E.M. Statistical analyzes are performed using the Annova test and considering the results significant with P <0.05.
    RESULTS
    The combination studied dendrimer / peptide (1A / IP, 1 / GHRH)) slows tumor growth and causes the death of cancer cells at low concentrations, leading to anticancer behavior (Fig. 3, dendrimer results 1). It should be noted that these peptides studied (VIP / GHRH) have protumoral activity and that although the dendritic systems used (1 and 2)
    They showed some anti-tumor activity, the combination with VIP and GHRH is much more effective. Subsequent trials showed that these nanoconjugates favored cell adhesion and avoided processes of migration of tumor cells (Fig. 4, 5, 6, results of dendrimer 1). This effect was contrasted with what they would have only the 5 dendrimero (1) and their inefficiency was observed in preventing adhesion and migration.
    In order to know if the treatments were producing apoptosis or any change in the cell cycle, flow cytometry tests were performed (Fig. 7, results for dendrimer 1). As you can see no treatment induces apoptosis, although 10 if there is a variation in the cell cycle for the treatments of peptides attached to! dendrimero. For these cases it is observed that the cycle is stopped in the synthesis phase (S), increasing the number of cells in this phase and decreasing the cells of the following phases (G2 and Mitosis).
    权利要求:
    Claims (11)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    35
    1. A combination of peptide and dendritic molecule, dendrimer or dendron, preferably of carbosilane structure but without ruling out others, called nanoconjugate.
    [2]
    2. The peptide according to the preceding claim is preferably a neuropeptide, preferably from the glucagon / secretin family.
    [3]
    3. Nanoconjugate according to the previous claim where the neuropeptide is the vasoactive intestinal peptide, VIP, the growth hormone-releasing hormone, GHRH, or the pituitary adenylate cyclase activating peptide, PACAP, without ruling out others having a similar activity.
    [4]
    4. Nanoconjugate according to claims 1 to 3, wherein the dendritic compound is a dendritic cradle or dendrimer. Preferably these compounds are cationic of carbosilane structure.
    [5]
    5. Compound according to any of the preceding claims, wherein the outer layer of dendritic molecules, dendrimers or dendrons, or the focal point of dendrons further comprises an additional function. These additional functions can be selected from a tag molecule, preferably a fluorophore, a leader group or an active ingredient.
    [6]
    6. Method for obtaining the nanoconjugates described according to any of claims 1 to 5, comprising a reaction between the peptide and the dendritic molecule or its combination in the appropriate medium.
    [7]
    7. Method for obtaining the nanoconjugates described according to any one of claims 1 to 6, wherein said reaction or combination is preferably carried out in the presence of a polar solvent such as water, DMSO or an R1-OH alcohol, wherein R1 is an alkyl group (C1-C10), or a mixture of them.
    [8]
    8. Use of the compounds described according to any of claims 1 to 5, as active ingredients for the development of an anticancer drug.
    [9]
    9. Use according to the preceding claim, where cancer is prostate cancer, preferably advanced prostate cancer.
    [10]
    10. Pharmaceutical composition comprising a nanoconjugate according to any
    5 of claims 1 to 5.
    [11]
    11. Pharmaceutical composition according to the preceding claim further comprising a pharmaceutically acceptable vehicle and / or other active ingredient, preferably an antibiotic, anti-inflammatory or anti-cancer.
    10
    类似技术:
    公开号 | 公开日 | 专利标题
    Wang et al.2017|Mechanism of surface charge triggered intestinal epithelial tight junction opening upon chitosan nanoparticles for insulin oral delivery
    KR101299821B1|2013-09-03|Composition for proteasome inhibition
    TWI394774B|2013-05-01|Novel block copolymers, microcell modifiers, and anticancer agents that are useful as an active ingredient
    AU2021200135A1|2021-03-18|Liposome compositions and methods of use thereof
    CN107669632B|2021-07-02|Drug carrier, micelle, drug preparation, preparation method and application thereof
    JP2000515542A|2000-11-21|Long-acting drugs and pharmaceutical compositions containing them
    BRPI0714761B1|2021-03-23|FORMULATIONS UNDERSTANDING CYCLIC COMPOUNDS
    Wang et al.2019|Self-assembling peptide-based nanodrug delivery systems
    ES2259674T3|2006-10-16|LIPOSOMAS OF ENCAPSULATION OF ANTI-CANCER DRUGS AND USE OF THE SAME IN THE TREATMENT OF MALIGNOUS TUMORS.
    WO2013119061A1|2013-08-15|Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
    US20160303186A1|2016-10-20|Cyclic-glur6 analogs, methods of treatment and use
    ES2677242A1|2018-07-31|Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against cancer |
    CN107903389B|2021-05-04|Synthesis and application of E-selectin-targeted polyethylene glycol two-end double-modified antitumor drug
    Ruan et al.2021|Stapled RAP12 peptide ligand of LRP1 for micelles-based multifunctional glioma-targeted drug delivery
    JP5807927B2|2015-11-10|Internal surface hydrophobized organic nanotube, and drug encapsulated product using the nanotube
    US8642555B2|2014-02-04|Prodrugs
    Zhang et al.2021|Cascaded amplification of intracellular oxidative stress and reversion of multidrug resistance by nitric oxide prodrug based-supramolecular hydrogel for synergistic cancer chemotherapy
    WO2019096095A1|2019-05-23|Integrin receptor-targeted anti-cancer conjugate
    EP3156411B1|2021-03-03|Artificial catalyst system capable of substituting for in vivo acylation function
    US20210038730A1|2021-02-11|Peptide nanofibers
    JP2000511511A|2000-09-05|Biologically active protein for tumor growth inhibition and capillary growth, collagen fragment HF-COLL-18 / 514cf
    EP3333177B1|2021-07-14|Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof
    CN108578369B|2021-05-04|Preparation and application of surface double-modified targeted human serum albumin nano-drug carrier
    Shu et al.2018|Anticancer activity and pharmacokinetics of TanshinoneⅡA derivative supramolecular hydrogels
    WO2006106633A1|2006-10-12|Uv-induced dermatitis inhibitor and atopic dermatitis inhibitor
    同族专利:
    公开号 | 公开日
    WO2018142007A1|2018-08-09|
    ES2677242B1|2019-03-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20060078535A1|2004-10-13|2006-04-13|The Regents Of The University Of Michigan|Anticancer compounds and methods|
    US20110268789A1|2008-09-25|2011-11-03|Min Li|Use of pituitary adenylate cyclase-activating polypeptide and pacap analogs as adjunctive treatments with anticancer agents|
    ES2444490A1|2012-07-25|2014-02-25|Universidad De Alcalá|Homo- and hetero-functionalised carbosilane dendritic compounds|
    US20160015823A1|2012-08-14|2016-01-21|Angiochem Inc.|Peptide-dendrimer conjugates and uses thereof|
    US20160122406A1|2013-06-07|2016-05-05|The Administrators Of The Tulane Educational Fund|Analogs of pituitary adenylate cyclase-activating polypeptide and methods for their use|
    法律状态:
    2018-07-31| BA2A| Patent application published|Ref document number: 2677242 Country of ref document: ES Kind code of ref document: A1 Effective date: 20180731 |
    2019-03-27| FG2A| Definitive protection|Ref document number: 2677242 Country of ref document: ES Kind code of ref document: B1 Effective date: 20190327 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201700069A|ES2677242B1|2017-01-31|2017-01-31|Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against cancer|ES201700069A| ES2677242B1|2017-01-31|2017-01-31|Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against cancer|
    PCT/ES2018/070062| WO2018142007A1|2017-01-31|2018-01-26|Nanoconjugates formed from dendritic molecules and peptides as antitumour agents against cancer|
    [返回顶部]